Fibronostics have achieved ISO27001:2022 certification 

Fibronostics is proud to announce that we have achieved ISO27001:2022 certification, another significant milestone in our company’s journey towards excellence in information security, cybersecurity and privacy protection. This certification symbolizes our unwavering commitment to safeguarding the confidentiality and integrity of sensitive patient information entrusted to us. It reflects the dedication of every individual within our […]

LIVERSTAT is now a Notified Medical Device

We are thrilled to announce that LIVERSTAT, our software as medical device (SaMD) has been officially listed as a Class A Medical Device by the Health Sciences Authority (HSA). This significant milestone marks a pivotal moment in our journey to revolutionize liver disease management.  LIVERSTAT utilizes data from common blood biomarkers and anthropometrics to provide […]

Meet our team this coming AASLD on Nov 11 to Nov 14 in Boston, MA

We’re excited to announce that Fibronostics will be attending AASLD on 11.10-11.14 in Boston, MA! We will be presenting 5 posters and can’t wait to network with others in the industry, learn more about advancements in liver health, and take home knowledge we can apply to our current processes. If you’ll also be in attendance, we’d […]

Fibronostics joining forces with Stone diagnostics for Enhanced Laboratory services

We are proud to announce today of our strategic partnership with STONE Diagnostics, a leading provider of laboratory services in the United States. STONE Diagnostics will provide Physicians and their patients end to end service to enable Physicians to assess chronic liver disease with Fibronostics’ benchmark product, LIVERFASt™. STONE Diagnostics‘ combination of scaled operational excellence and leading digital capabilities […]

Fibronostics will be at the EASL2023 congress in Vienna!

Fibronostics will be guests at the EASL congress in Vienna, Austria to present ‘NAFLD: Diagnostics and non-invasive assessment’. Join Dr. Mona Munteanu, our Chief Scientific Officer, on 24 June between 09:00 – 17:00 where she will discuss ‘LIVERSTAT, first-line screening tool in at-risk MAFLD patients outperforms the standard-of-care (SOC) FIB-4’ We can’t wait to network with others in the industry, learn […]